

# J Steven Leeder

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/807749/publications.pdf>

Version: 2024-02-01

218  
papers

13,119  
citations

26610

56  
h-index

26591

107  
g-index

250  
all docs

250  
docs citations

250  
times ranked

13211  
citing authors

#	ARTICLE	IF	CITATIONS
1	Recent advances in the ontogeny of drug disposition. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4267-4284.	1.1	13
2	Ontogeny of Scaling Factors for Pediatric Physiology-Based Pharmacokinetic Modeling and Simulation: Microsomal Protein Per Gram of Liver. <i>Drug Metabolism and Disposition</i> , 2022, 50, 24-32.	1.7	6
3	The Impact of Age and Genetics on Naltrexone Biotransformation. <i>Drug Metabolism and Disposition</i> , 2022, 50, 168-173.	1.7	7
4	Utility of the 13 C-antoprazole breath test as a CYP2C19 phenotyping probe for children. <i>Clinical and Translational Science</i> , 2022, , .	1.5	1
5	Pediatric growth patterns in youth-onset type 2 diabetes mellitus: Implications for physiologically-based pharmacokinetic models. <i>Clinical and Translational Science</i> , 2022, 15, 912-922.	1.5	3
6	Genomic answers for children: Dynamic analyses of >1000 pediatric rare disease genomes. <i>Genetics in Medicine</i> , 2022, 24, 1336-1348.	1.1	37
7	Interindividual Variability and Differential Tissue Abundance of Mitochondrial Amidoxime Reducing Component Enzymes in Humans. <i>Drug Metabolism and Disposition</i> , 2022, 50, 191-196.	1.7	4
8	Clinical Implications of Altered Drug Transporter Abundance/Function and PBPK Modeling in Specific Populations: An ITC Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 501-526.	2.3	21
9	Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 888-896.	2.3	212
10	Are body surface area (BSA) based estimates of liver volume applicable to children with overweight or obesity? An in vivo validation study. <i>Clinical and Translational Science</i> , 2021, 14, 2008-2016.	1.5	6
11	Analysis Approaches to Identify Pharmacogenetic Associations With Pharmacodynamics. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 589-594.	2.3	9
12	Ontogeny of Drug-Metabolizing Enzymes. <i>Methods in Molecular Biology</i> , 2021, 2342, 551-593.	0.4	13
13	The impact of the CYP2D6 enhancer single nucleotide polymorphism on CYP2D6 activity. <i>Clinical Pharmacology and Therapeutics</i> , 2021, , .	2.3	3
14	A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 50-52.	2.3	22
15	Alternative Splicing of the SLCO1B1 Gene: An Exploratory Analysis of Isoform Diversity in Pediatric Liver. <i>Clinical and Translational Science</i> , 2020, 13, 509-519.	1.5	9
16	Normalized Testosterone Glucuronide as a Potential Urinary Biomarker for Highly Variable UGT2B17 in Children 7-18 Years. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1149-1158.	2.3	6
17	Functional Consequences of Pravastatin Isomerization on OATP1B1-Mediated Transport. <i>Drug Metabolism and Disposition</i> , 2020, 48, 1192-1198.	1.7	5
18	Ontogeny Related Changes in the Pediatric Liver Metabolome. <i>Frontiers in Pediatrics</i> , 2020, 8, 549.	0.9	3

#	ARTICLE	IF	CITATIONS
19	The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites. <i>Drug Metabolism and Disposition</i> , 2020, 48, 1113-1120.	1.7	5
20	Effect of Intrauterine Smoke Exposure on microRNA-15a Expression in Human Lung Development and Subsequent Asthma Risk. <i>Healthcare (Switzerland)</i> , 2020, 8, 536.	1.0	5
21	Long-Distance Phasing of a Tentative "Enhancer" Single-Nucleotide Polymorphism With CYP2D6 Star Allele Definitions. <i>Frontiers in Pharmacology</i> , 2020, 11, 486.	1.6	10
22	Impact of <i>SLCO1B1</i> Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia. <i>Clinical and Translational Science</i> , 2020, 13, 628-637.	1.5	12
23	Cost and Potential Avoidability of Antibiotic-Associated Adverse Drug Reactions in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2019, 8, 66-68.	0.6	15
24	Age- and Genotype-Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate-Glucuronosyltransferases in Human Liver. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 131-141.	2.3	87
25	Optimized Renal Transporter Quantification by Using Aquaporin 1 and Aquaporin 2 as Anatomical Markers: Application in Characterizing the Ontogeny of Renal Transporters and Its Correlation with Hepatic Transporters in Paired Human Samples. <i>AAPS Journal</i> , 2019, 21, 88.	2.2	33
26	Who Believes They Are "Just Average"? Informing the Treatment of Individual Patients Using Population Data. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 939-941.	2.3	6
27	Ontogeny of Hepatic Sulfotransferases and Prediction of Age-Dependent Fractional Contribution of Sulfation in Acetaminophen Metabolism. <i>Drug Metabolism and Disposition</i> , 2019, 47, 818-831.	1.7	42
28	A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1227-1235.	0.8	5
29	Clinical Pharmacogenetics Implementation Consortium Guideline for <i>Cytochrome P450 (CYP2D6) Genotype and Atomoxetine Therapy</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 94-102.	2.3	152
30	Evaluating metronidazole as a novel, safe CYP2A6 phenotyping probe in healthy adults. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 960-969.	1.1	4
31	Examining the Role of Precision Medicine with Oral Baclofen in Pediatric Patients with Cerebral Palsy. <i>Current Physical Medicine and Rehabilitation Reports</i> , 2019, 7, 40-45.	0.3	4
32	The effect of race and supplementation on maternal and umbilical cord plasma folates. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2019, 34, 1-9.	0.7	3
33	Impact of Genetic Variation on Pravastatin Systemic Exposure in Pediatric Hypercholesterolemia. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1501-1512.	2.3	19
34	Considerations for Implementing Precision Therapeutics for Children. <i>Clinical and Translational Science</i> , 2019, 12, 140-150.	1.5	17
35	Examining the role of precision medicine with oral baclofen in pediatric patients with cerebral palsy. <i>Current Physical Medicine and Rehabilitation Reports</i> , 2019, 7, 40-45.	0.3	0
36	Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 778-786.	2.3	110

#	ARTICLE	IF	CITATIONS
37	Response to Aprepitant and fosaprepitant decrease the effectiveness of hormonal contraceptives™. British Journal of Clinical Pharmacology, 2018, 84, 604-604.	1.1	1
38	Impact of <i>SLCO1B1</i> Genotype on Pediatric Simvastatin Acid Pharmacokinetics. Journal of Clinical Pharmacology, 2018, 58, 823-833.	1.0	33
39	PharmGKB summary. Pharmacogenetics and Genomics, 2018, 28, 110-115.	0.7	12
40	Hepatic Abundance and Activity of Androgen- and Drug-Metabolizing Enzyme UGT2B17 Are Associated with Genotype, Age, and Sex. Drug Metabolism and Disposition, 2018, 46, 888-896.	1.7	42
41	The NSIGHT1-randomized controlled trial: rapid whole-genome sequencing for accelerated etiologic diagnosis in critically ill infants. Npj Genomic Medicine, 2018, 3, 6.	1.7	156
42	Ontogeny-related pharmacogene changes in the pediatric liver transcriptome. Pharmacogenetics and Genomics, 2018, 28, 86-94.	0.7	12
43	Nicotinamide Phosphoribosyltransferase Deficiency Potentiates the Antiproliferative Activity of Methotrexate through Enhanced Depletion of Intracellular ATP. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 96-106.	1.3	7
44	Novel Protective Role of Nicotinamide Phosphoribosyltransferase in Acetaminophen-Induced Acute Liver Injury in Mice. American Journal of Pathology, 2018, 188, 1640-1652.	1.9	11
45	Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children With Cerebral Palsy. PM and R, 2018, 10, 235-243.	0.9	24
46	Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis. Clinical Pharmacology and Therapeutics, 2018, 103, 390-394.	2.3	15
47	The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 ( <i>CYP</i> ) Allele Nomenclature Database. Clinical Pharmacology and Therapeutics, 2018, 103, 399-401.	2.3	335
48	Pharmacogenomics and implementation of precision therapeutics in the neonatal ICU: a new frontier?. Pharmacogenomics, 2018, 19, 1231-1233.	0.6	5
49	Proteomics of human liver membrane transporters: a focus on fetuses and newborn infants. European Journal of Pharmaceutical Sciences, 2018, 124, 217-227.	1.9	36
50	The benzylic alcohol metabolite of trimethoprim covalently binds to proteins in vitro. Drug Metabolism and Pharmacokinetics, 2018, 33, S79.	1.1	0
51	Ten Years™ Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics. Journal of Personalized Medicine, 2018, 8, 15.	1.1	110
52	Intensive and prolonged urine collection in preterm infants reveals three distinct indomethacin metabolic patterns: potential implications for drug dosing. Pediatric Research, 2018, 84, 325-327.	1.1	6
53	Constitutive Activation of Stat Signaling in Fibroblast-like Synoviocytes Derived from Patients with Juvenile Idiopathic Arthritis Is Inhibited by Methotrexate. FASEB Journal, 2018, 32, lb663.	0.2	0
54	Prediction of CYP2D6 phenotype from genotype across world populations. Genetics in Medicine, 2017, 19, 69-76.	1.1	365

#	ARTICLE	IF	CITATIONS
55	Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants. <i>Drug Metabolism and Disposition</i> , 2017, 45, 216-223.	1.7	74
56	Aprepitant and fosaprepitant drug interactions: a systematic review. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2148-2162.	1.1	62
57	Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase. <i>Cell Death and Disease</i> , 2017, 8, e2705-e2705.	2.7	54
58	Genetic and Nongenetic Factors Associated with Protein Abundance of Flavin-Containing Monooxygenase 3 in Human Liver. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 363, 265-274.	1.3	43
59	Early pregnancy intrauterine fetal exposure to maternal smoking and impact on fetal telomere length. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 218, 27-32.	0.5	21
60	Age-dependent Protein Abundance of Cytosolic Alcohol and Aldehyde Dehydrogenases in Human Liver. <i>Drug Metabolism and Disposition</i> , 2017, 45, 1044-1048.	1.7	25
61	Metronidazole Metabolism in Neonates and the Interplay Between Ontogeny and Genetic Variation. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 230-234.	1.0	4
62	5.2 Use of Genetic Information in Clinical Practice: Leveraging Available Experience to Implement Precision Therapeutics in Children. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017, 56, S8.	0.3	0
63	Design and Testing of an EHR-Integrated, Busulfan Pharmacokinetic Decision Support Tool for the Point-of-Care Clinician. <i>Frontiers in Pharmacology</i> , 2016, 7, 65.	1.6	25
64	Dynamics of Cytosine Methylation in the Proximal Promoters of CYP3A4 and CYP3A7 in Pediatric and Prenatal Livers. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1020-1026.	1.7	12
65	Decreased Pregnane X Receptor Expression in Children with Active Crohns Disease. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1066-1069.	1.7	19
66	Constellation: a tool for rapid, automated phenotype assignment of a highly polymorphic pharmacogene, CYP2D6, from whole-genome sequences. <i>Npj Genomic Medicine</i> , 2016, 1, 15007.	1.7	93
67	Validation of Saliva and Buccal Swabs for Recipient DNA after Pediatric Allogeneic HSCT. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S265.	2.0	0
68	Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 642-650.	2.3	54
69	Challenges and Opportunities for Increasing the Knowledge Base Related to Drug Biotransformation and Pharmacokinetics during Growth and Development. <i>Drug Metabolism and Disposition</i> , 2016, 44, 916-923.	1.7	17
70	Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1070-1079.	1.7	23
71	Age, Sexual Dimorphism, and Disease Associations in the Developing Human Fetal Lung Transcriptome. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 54, 814-821.	1.4	28
72	Developmental Expression of CYP2B6: A Comprehensive Analysis of mRNA Expression, Protein Content and Bupropion Hydroxylase Activity and the Impact of Genetic Variation. <i>Drug Metabolism and Disposition</i> , 2016, 44, 948-958.	1.7	37

#	ARTICLE	IF	CITATIONS
73	Quantification of pravastatin acid, lactone and isomers in human plasma by UHPLC-MS/MS and its application to a pediatric pharmacokinetic study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1012-1013, 169-177.	1.2	6
74	CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation. <i>International Journal of Experimental Pathology</i> , 2015, 96, 81-86.	0.6	15
75	Meaningful Use and Clinical Utility of Preemptive Pharmacogenetic Testing: (Re)View From a CYP2D6 Poor Metabolizer. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 119-121.	2.3	7
76	Effect of CYP3A5*3 on asthma control among children treated with inhaled beclomethasone. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 505-507.	1.5	12
77	In Vitro Hepatic Oxidative Biotransformation of Trimethoprim. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1372-1380.	1.7	23
78	SNP genotyping using TaqMan <sup>®</sup> technology: the CYP2D6*17 assay conundrum. <i>Scientific Reports</i> , 2015, 5, 9257.	1.6	24
79	Over-the-Counter Medications: Update on Cough and Cold Preparations. <i>Pediatrics in Review</i> , 2015, 36, 286-298.	0.2	17
80	Development and Application of a High-Throughput Screening Method to Evaluate Antifungal Activity against <i>Trichophyton tonsurans</i> . <i>Journal of Biomolecular Screening</i> , 2015, 20, 1171-1177.	2.6	4
81	Variability in Expression of CYP3A5 in Human Fetal Liver. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1286-1293.	1.7	20
82	CYP2D6 Haplotype Determination Using Long Range Allele-Specific Amplification. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 740-748.	1.2	38
83	Glucocorticoid Genes and the Developmental Origins of Asthma Susceptibility and Treatment Response. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2015, 52, 543-553.	1.4	22
84	CYP2D7 Sequence Variation Interferes with TaqMan CYP2D6*15 and *35 Genotyping. <i>Frontiers in Pharmacology</i> , 2015, 6, 312.	1.6	13
85	Effect of Intrathecal Methotrexate on CSF and RBC Folate Levels in Children Receiving Treatment for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 2486-2486.	0.6	0
86	Over-the-Counter Medications: Update on Cough and Cold Preparations. <i>Pediatrics in Review</i> , 2015, 36, 286-298.	0.2	2
87	A modified generalized Fisher method for combining probabilities from dependent tests. <i>Frontiers in Genetics</i> , 2014, 5, 32.	1.1	57
88	Fetal lung and placental methylation is associated with in utero nicotine exposure. <i>Epigenetics</i> , 2014, 9, 1473-1484.	1.3	88
89	Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics. <i>Pharmacogenomics</i> , 2014, 15, 1947-1962.	0.6	39
90	Reference intervals for urinary renal injury biomarkers KIM-1 and NGAL in healthy children. <i>Biomarkers in Medicine</i> , 2014, 8, 1189-1197.	0.6	50

#	ARTICLE	IF	CITATIONS
91	Individualizing the Use of Medications in Children: Making Goldilocks Happy. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 304-306.	2.3	14
92	Ontogeny of Human Hepatic and Intestinal Transporter Gene Expression during Childhood: Age Matters. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1268-1274.	1.7	124
93	Folate Depletion and Increased Glutamation in Juvenile Idiopathic Arthritis Patients Treated With Methotrexate. <i>Arthritis and Rheumatology</i> , 2014, 66, 3476-3485.	2.9	14
94	<i>CYP2D6</i> and pharmacogenomics: where does future research need to focus? Part 2: clinical aspects. <i>Pharmacogenomics</i> , 2014, 15, 1055-1058.	0.6	7
95	<i>CYP2D6</i> and pharmacogenomics: where does future research need to focus? Part 1: technical aspects. <i>Pharmacogenomics</i> , 2014, 15, 407-410.	0.6	9
96	Urinary Biomarkers of Trimethoprim Bioactivation in Vivo Following Therapeutic Dosing in Children. <i>Chemical Research in Toxicology</i> , 2014, 27, 211-218.	1.7	10
97	Effect of CYP3A5 genotype, steroids, and azoles on tacrolimus in a pediatric renal transplant population. <i>Pediatric Nephrology</i> , 2014, 29, 2039-2049.	0.9	14
98	Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. <i>Human Molecular Genetics</i> , 2014, 23, 268-278.	1.4	101
99	Population Pharmacokinetics of Oral Baclofen in Pediatric Patients with Cerebral Palsy. <i>Journal of Pediatrics</i> , 2014, 164, 1181-1188.e8.	0.9	29
100	<i>VKORC1</i> and <i>CYP2C9</i> genotypes are predictors of warfarin-related outcomes in children. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1055-1062.	0.8	36
101	Relative Oral Bioequivalence of Two 6-Mercaptopurine (6-MP) Liquid Formulations in Children with Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2014, 124, 2242-2242.	0.6	0
102	Risk score modeling of multiple gene to gene interactions using aggregated-multifactor dimensionality reduction. <i>BioData Mining</i> , 2013, 6, 1.	2.2	23
103	Epigenetic Regulation of ADME-Related Genes: Focus on Drug Metabolism and Transport. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1721-1724.	1.7	29
104	Fluticasone Propionate Pharmacogenetics: CYP3A4*22 Polymorphism and Pediatric Asthma Control. <i>Journal of Pediatrics</i> , 2013, 162, 1222-1227.e2.	0.9	50
105	Age Related Changes in Fractional Elimination Pathways for Drugs: Assessing the Impact of Variable Ontogeny on Metabolic Drug-Drug Interactions. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 857-865.	1.0	53
106	Anticonvulsant Agents. , 2013, , 423-441.		4
107	High-resolution melt analysis to detect sequence variations in highly homologous gene regions: application to <i>CYP2B6</i> . <i>Pharmacogenomics</i> , 2013, 14, 913-922.	0.6	10
108	Low-Dose Methotrexate Results in the Selective Accumulation of Aminoimidazole Carboxamide Ribotide in an Erythroblastoid Cell Line. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 347, 154-163.	1.3	18

#	ARTICLE	IF	CITATIONS
109	Trends in Adverse Reactions to Trimethoprim-Sulfamethoxazole. <i>Pediatrics</i> , 2013, 131, e103-e108.	1.0	17
110	Decreased Expression of Nicotinamide Phosphoribosyltransferase in Patients with Juvenile Idiopathic Arthritis Receiving Methotrexate. <i>Journal of Rheumatology</i> , 2013, 40, 741-742.	1.0	3
111	Pediatric Pharmacovigilance: Enhancing Adverse Drug Reaction Reporting in a Tertiary Care Children's Hospital. <i>Therapeutic Innovation and Regulatory Science</i> , 2013, 47, 566-571.	0.8	14
112	Cotinine in Human Placenta Predicts Induction of Gene Expression in Fetal Tissues. <i>Drug Metabolism and Disposition</i> , 2013, 41, 305-311.	1.7	28
113	Variability of Histamine Pharmacodynamic Response in Children With Allergic Rhinitis. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 731-737.	1.0	7
114	Valproic acid pathway. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 236-241.	0.7	270
115	CYP2D6 expression is regulated by polymorphisms that affect splicing and transcription: new biomarkers for CYP2D6 activity. <i>FASEB Journal</i> , 2013, 27, 663.6.	0.2	0
116	Impact of development and genetic variation on human hepatic CYP2B6 expression and activity.. <i>FASEB Journal</i> , 2013, 27, 270.1.	0.2	0
117	The Role of CYP3A4 mRNA Transcript with Shortened 3'-Untranslated Region in Hepatocyte Differentiation, Liver Development, and Response to Drug Induction. <i>Molecular Pharmacology</i> , 2012, 81, 86-96.	1.0	10
118	Interpreting Pharmacogenetic Data in the Developing Neonate: The Challenge of Hitting a Moving Target. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 434-6.	2.3	31
119	PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 466-470.	0.7	68
120	Pediatric Pharmacogenomics. <i>Pediatric Clinics of North America</i> , 2012, 59, 1017-1037.	0.9	11
121	Global tests of P-values for multifactor dimensionality reduction models in selection of optimal number of target genes. <i>BioData Mining</i> , 2012, 5, 3.	2.2	7
122	Comprehensive quantitative measurement of folate polyglutamates in human erythrocytes by ion pairing ultra-performance liquid chromatography/tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2012, 26, 1617-1630.	0.7	16
123	CYP2D6, SULT1A1 and UGT2B17 copy number variation: quantitative detection by multiplex PCR. <i>Pharmacogenomics</i> , 2012, 13, 91-111.	0.6	66
124	Drug Administration and Pharmacogenomics in Children Receiving Acute or Chronic Renal Replacement Therapy. , 2012, , 609-627.		0
125	Betaine-homocysteine methyltransferase: Human liver genotype-phenotype correlation. <i>Molecular Genetics and Metabolism</i> , 2011, 102, 126-133.	0.5	38
126	PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 679-686.	0.7	120



#	ARTICLE	IF	CITATIONS
127	PharmGKB summary. Pharmacogenetics and Genomics, 2011, 21, 906-910.	0.7	77
128	Developmental variations in metabolic capacity of flavin-containing monoxygenase 3 in childhood. British Journal of Clinical Pharmacology, 2011, 71, 585-591.	1.1	24
129	Effects of Valproic Acid on Organic Acid Metabolism in Children: A Metabolic Profiling Study. Clinical Pharmacology and Therapeutics, 2011, 89, 867-874.	2.3	45
130	Expression analysis of asthma candidate genes during human and murine lung development. Respiratory Research, 2011, 12, 86.	1.4	55
131	The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. Arthritis and Rheumatism, 2011, 63, 276-285.	6.7	61
132	NTP-CERHR expert panel report on the developmental toxicity of soy infant formula. Birth Defects Research Part B: Developmental and Reproductive Toxicology, 2011, 92, 421-468.	1.4	81
133	Measurement of methotrexate polyglutamates in human erythrocytes by ion-pair UPLC-MS/MS. Bioanalysis, 2011, 3, 2783-2796.	0.6	16
134	Genetic Transmission of Cytochrome P450 2D6 (CYP2D6) Ultrarapid Metabolism: Implications for Breastfeeding Women taking Codeine. Current Drug Safety, 2011, 6, 36-39.	0.3	21
135	Development of biomarkers to optimize pediatric patient management: what makes children different?. Biomarkers in Medicine, 2011, 5, 781-794.	0.6	49
136	Alternative CYP3A4 mRNA Isoforms Are Related to Hepatocyte Differentiation, Liver Development, and Response to Drugs. FASEB Journal, 2011, 25, 1014.8.	0.2	0
137	Divergence Among an International Population of Trichophyton tonsurans Isolates. Mycopathologia, 2010, 169, 1-13.	1.3	34
138	Analysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: Effect of route of administration on variability in intracellular methotrexate polyglutamate concentrations. Arthritis and Rheumatism, 2010, 62, 1803-1812.	6.7	57
139	Identification of Novel CYP2D7-2D6 Hybrids: Non-Functional and Functional Variants. Frontiers in Pharmacology, 2010, 1, 121.	1.6	58
140	Impact of the CYP2C19*17 Allele on the Pharmacokinetics of Omeprazole and Pantoprazole in Children: Evidence for a Differential Effect. Drug Metabolism and Disposition, 2010, 38, 894-897.	1.7	55
141	Developmental Pharmacogenetics in Pediatric Rheumatology: Utilizing a New Paradigm to Effectively Treat Patients with Juvenile Idiopathic Arthritis with Methotrexate. Human Genomics and Proteomics, 2010, 2, 257120.	1.5	10
142	UGT2B17 and SULT1A1 gene copy number variation (CNV) detection by LabChip microfluidic technology. Clinical Chemistry and Laboratory Medicine, 2010, 48, 627-33.	1.4	4
143	Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Research, 2010, 20, 1020-1036.	2.4	231
144	Understanding the Relative Roles of Pharmacogenetics and Ontogeny in Pediatric Drug Development and Regulatory Science. Journal of Clinical Pharmacology, 2010, 50, 1377-1387.	1.0	79

#	ARTICLE	IF	CITATIONS
145	Selective Toll-Like Receptor Expression in Human Fetal Lung. <i>Pediatric Research</i> , 2010, 68, 335-338.	1.1	23
146	Identifying genomic and developmental causes of adverse drug reactions in children. <i>Pharmacogenomics</i> , 2010, 11, 1591-1602.	0.6	32
147	Transcriptomic Analysis of Human Lung Development. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 54-63.	2.5	107
148	CYP2D7-CYP2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. <i>Pharmacogenomics</i> , 2010, 11, 43-53.	0.6	63
149	Expedient methodology for total methotrexate polyglutamation pool determination in human erythrocytes. <i>Analytical Methods</i> , 2010, 2, 831.	1.3	5
150	Determinants of Variability in Divalproex Sodium (VPA) Glucuronidation in Children. <i>FASEB Journal</i> , 2010, 24, .	0.2	0
151	Personalized Medicine: Reality and Reality Checks. <i>Annals of Pharmacotherapy</i> , 2009, 43, 963-966.	0.9	6
152	Platform dependence of inference on gene-wise and gene-set involvement in human lung development. <i>BMC Bioinformatics</i> , 2009, 10, 189.	1.2	4
153	A novel high-performance liquid chromatography/mass spectrometry method for improved selective and sensitive measurement of methotrexate polyglutamation status in human red blood cells. <i>Rapid Communications in Mass Spectrometry</i> , 2009, 23, 3693-3702.	0.7	36
154	Developmental Pharmacogenetics: A General Paradigm for Application to Neonatal Pharmacology and Toxicology. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 678-682.	2.3	40
155	Interindividual variability in acetaminophen sulfation by human fetal liver: Implications for pharmacogenetic investigations of drug-induced birth defects. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2008, 82, 155-165.	1.6	66
156	A Comparative Study on Computational Two-Block Motif Detection: Algorithms and Applications. <i>Molecular Pharmaceutics</i> , 2008, 5, 3-16.	2.3	17
157	Pathways of Carbamazepine Bioactivation in Vitro. III. The Role of Human Cytochrome P450 Enzymes in the Formation of 2,3-Dihydroxycarbamazepine. <i>Drug Metabolism and Disposition</i> , 2008, 36, 1637-1649.	1.7	81
158	CYP3A4-Mediated Carbamazepine (CBZ) Metabolism: Formation of a Covalent CBZ-CYP3A4 Adduct and Alteration of the Enzyme Kinetic Profile. <i>Drug Metabolism and Disposition</i> , 2008, 36, 490-499.	1.7	54
159	Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. <i>Genetics in Medicine</i> , 2008, 10, 720-729.	1.1	48
160	Evaluation of a [ <sup>13</sup> C]-Dextromethorphan Breath Test to Assess CYP2D6 Phenotype. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 1041-1051.	1.0	31
161	Cytochrome P4502D6 (CYP2D6) Gene Locus Heterogeneity: Characterization of Gene Duplication Events. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 242-251.	2.3	143
162	Ontogeny of Dextromethorphan O- and N-demethylation in the First Year of Life. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 510-516.	2.3	160

#	ARTICLE	IF	CITATIONS
163	Application of Pharmacogenomic Strategies to the Study of Drug-induced Birth Defects. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 595-599.	2.3	8
164	Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. <i>Canadian Family Physician</i> , 2007, 53, 33-5.	0.1	125
165	Effect of Diet on the Development of Drug Metabolism by Cytochrome P-450 Enzymes in Healthy Infants. <i>Pediatric Research</i> , 2006, 60, 717-723.	1.1	79
166	Variability of CYP2J2 Expression in Human Fetal Tissues. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 523-532.	1.3	47
167	Multiple Dose Pharmacokinetics of Paroxetine in Children and Adolescents with Major Depressive Disorder or Obsessive-Compulsive Disorder. <i>Neuropsychopharmacology</i> , 2006, 31, 1274-1285.	2.8	43
168	BIOTRANSFORMATION OF FLUTICASONE: IN VITRO CHARACTERIZATION. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1035-1040.	1.7	55
169	NUCLEAR RECEPTOR EXPRESSION IN FETAL AND PEDIATRIC LIVER: CORRELATION WITH CYP3A EXPRESSION. <i>Drug Metabolism and Disposition</i> , 2006, 34, 131-137.	1.7	64
170	CYP2D6*36 GENE ARRANGEMENTS WITHIN THE CYP2D6 LOCUS: ASSOCIATION OF CYP2D6*36 WITH POOR METABOLIZER STATUS. <i>Drug Metabolism and Disposition</i> , 2006, 34, 563-569.	1.7	89
171	Effect of a Triphasic Oral Contraceptive on Drug-Metabolizing Enzyme Activity as Measured by the Validated Cooperstown 5+1 Cocktail. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 1413-1421.	1.0	48
172	Limited Association of the 2988G>A Single Nucleotide Polymorphism with CYP2D6*41 in Black Subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 228-230.	2.3	26
173	Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. <i>Pharmacogenomics Journal</i> , 2005, 5, 173-182.	0.9	67
174	Variability of CYP3A7 Expression in Human Fetal Liver. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 626-635.	1.3	122
175	Pathways of Carbamazepine Bioactivation In Vitro II. The Role of Human Cytochrome P450 Enzymes in the Formation of 2-Hydroxyiminostilbene. <i>Drug Metabolism and Disposition</i> , 2005, 33, 1819-26.	1.7	58
176	CYP2D7 splice variants in human liver and brain: Does CYP2D7 encode functional protein?. <i>Biochemical and Biophysical Research Communications</i> , 2005, 336, 1241-1250.	1.0	31
177	Ontogeny of drug metabolizing enzymes in the neonate. <i>Seminars in Fetal and Neonatal Medicine</i> , 2005, 10, 123-138.	1.1	161
178	Development and Refinement of Pregnane X Receptor (PXR) DNA Binding Site Model Using Information Theory. <i>Journal of Biological Chemistry</i> , 2004, 279, 46779-46786.	1.6	38
179	Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond. <i>Drug Discovery Today</i> , 2004, 9, 567-573.	3.2	39
180	Pharmacokinetics and genotypes do not predict metoprolol adverse events or efficacy in hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 536-544.	2.3	134

#	ARTICLE	IF	CITATIONS
181	Comparison of Various Urine Collection Intervals for Caffeine and Dextromethorphan Phenotyping in Children. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 708-714.	1.0	8
182	Cisapride: A potential model substrate to assess cytochrome P4503A4 activity in vivo. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 209-222.	2.3	9
183	Genome-wide prediction, display and refinement of binding sites with information theory-based models. <i>BMC Bioinformatics</i> , 2003, 4, 38.	1.2	18
184	Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D6*42, in African American subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 575-576.	2.3	25
185	Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 437-447.	2.3	129
186	Bioactivation of Clozapine by Murine Cardiac Tissue in Vivo and in Vitro. <i>Chemical Research in Toxicology</i> , 2003, 16, 1359-1364.	1.7	46
187	Developmental Pharmacology " Drug Disposition, Action, and Therapy in Infants and Children. <i>New England Journal of Medicine</i> , 2003, 349, 1157-1167.	13.9	1,986
188	CYP2D6 Poor Metabolizer Status Can Be Ruled Out by a Single Genotyping Assay for the "1584G Promoter Polymorphism. <i>Clinical Chemistry</i> , 2003, 49, 1008-1011.	1.5	70
189	Developmental and pediatric pharmacogenomics. <i>Pharmacogenomics</i> , 2003, 4, 331-341.	0.6	50
190	Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 207-218.	5.7	66
191	Pathways of Carbamazepine Bioactivation in Vitro I. Characterization of Human Cytochromes P450 Responsible for the Formation of 2- and 3-Hydroxylated Metabolites. <i>Drug Metabolism and Disposition</i> , 2002, 30, 1170-1179.	1.7	120
192	Characterization of Cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 Activities toward Model CYP2D6 Substrates Dextromethorphan, Bufuralol, and Debrisoquine. <i>Drug Metabolism and Disposition</i> , 2002, 30, 595-601.	1.7	56
193	Cytochrome P450 pharmacogenetics and anaesthesia. <i>Paediatric Anaesthesia</i> , 2002, 12, 810-811.	0.6	2
194	Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans*. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 72, 76-89.	2.3	178
195	Ontogeny of drug-metabolizing enzymes and its influence on the pathogenesis of adverse drug reactions in children. <i>Current Therapeutic Research</i> , 2001, 62, 900-912.	0.5	21
196	PHARMACOGENETICS AND PHARMACOGENOMICS. <i>Pediatric Clinics of North America</i> , 2001, 48, 765-782.	0.9	62
197	Acetaminophen Intoxication During Treatment: What You Don't Know Can Hurt You. <i>Clinical Pediatrics</i> , 2000, 39, 133-144.	0.4	29
198	Glucuronidation in Humans. <i>Clinical Pharmacokinetics</i> , 1999, 36, 439-452.	1.6	346

#	ARTICLE	IF	CITATIONS
199	Cytochrome P450 3A. <i>Clinical Pharmacokinetics</i> , 1999, 37, 485-505.	1.6	480
200	Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. <i>Pharmacogenetics and Genomics</i> , 1999, 9, 669-682.	5.7	41
201	Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. <i>Pharmacogenetics and Genomics</i> , 1999, 9, 669-682.	0.7	142
202	Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 63, 540-551.	2.3	86
203	Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 257-268.	2.3	70
204	Mechanisms of Idiosyncratic Hypersensitivity Reactions to Antiepileptic Drugs. <i>Epilepsia</i> , 1998, 39, S8-S16.	2.6	128
205	Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. <i>Pharmacogenetics and Genomics</i> , 1998, 8, 403-410.	5.7	66
206	Non-monoxygenase cytochromes P450 as potential human autoantigens in anticonvulsant hypersensitivity reactions. <i>Pharmacogenetics and Genomics</i> , 1998, 8, 211-226.	5.7	18
207	Tissue-Specific Expression and Alternative Splicing of Human Microsomal Epoxide Hydrolase. <i>DNA and Cell Biology</i> , 1997, 16, 1257-1266.	0.9	20
208	PHARMACOGENETICS IN PEDIATRICS. <i>Pediatric Clinics of North America</i> , 1997, 44, 55-77.	0.9	189
209	Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. <i>Nature</i> , 1996, 379, 645-648.	13.7	879
210	Developmental Aspects of Drug Metabolism in Children. <i>Drug Information Journal</i> , 1996, 30, 1135-1143.	0.5	6
211	Cellular toxicity of sulfamethoxazole reactive metabolitesâ€”I. <i>Biochemical Pharmacology</i> , 1991, 41, 567-574.	2.0	24
212	Cellular toxicity of sulfamethoxazole reactive metabolitesâ€”II. <i>Biochemical Pharmacology</i> , 1991, 41, 575-583.	2.0	18
213	Exogenous but not endogenous EBV induces lymphomas in beige/nude/xid mice carrying human lymphoid xenografts. <i>International Immunology</i> , 1991, 3, 731-735.	1.8	11
214	A Method for Meta-Analysis of Epidemiological Studies. <i>Drug Intelligence &amp; Clinical Pharmacy</i> , 1988, 22, 813-824.	0.4	101
215	Cerebrospinal Fluid Pharmacokinetics of Tobramycin, Ceftazidime, Phenobarbitone and Phenytoin in a Child. <i>Clinical Pharmacokinetics</i> , 1985, 10, 371-375.	1.6	2
216	Ceftazidime disposition in acute and stable cystic fibrosis. <i>Clinical Pharmacology and Therapeutics</i> , 1984, 36, 355-362.	2.3	73

#	ARTICLE	IF	CITATIONS
217	Glucagon Therapy for $\beta_2$ -Blocker Overdose. Drug Intelligence & Clinical Pharmacy, 1984, 18, 394-398.	0.4	50
218	Application of Pharmacogenetics and Pharmacogenomics in Pediatrics: What Makes Children Different?. , 0, , 249-262.		0